Similar articles

• The use of lipid-lowering drug therapy in children and adolescents.

  Avis HJ, Vissers MN, Wijburg FA, Kastelein JJ, Hutten BA. Avis HJ, et al. Curr Opin Investig Drugs. 2009 Mar;10(3):224-31. Curr Opin Investig Drugs. 2009. PMID: 19333879 Review.
• Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.

  Fazio S. Fazio S. Clin Ther. 2008 Feb;30(2):294-306. doi: 10.1016/j.clinthera.2008.02.004. Clin Ther. 2008. PMID: 18343268 Review.
• Drugs for lipids.

  [No authors listed] [No authors listed] Treat Guidel Med Lett. 2005 Mar;3(31):15-22. Treat Guidel Med Lett. 2005. PMID: 15726011 Review. No abstract available.
• Dyslipidaemia in diabetes.

  Patel J. Patel J. Clin Evid. 2006 Jun;(15):555-75. Clin Evid. 2006. PMID: 16973026 Review. No abstract available.
• Is it necessary to add fibrate to statin therapy in the management of dyslipidemia of metabolic syndrome?

  Turhan H, Yetkin E. Turhan H, et al. Int J Cardiol. 2006 Jun 16;110(2):276-7. doi: 10.1016/j.ijcard.2005.11.027. Epub 2005 Dec 20. Int J Cardiol. 2006. PMID: 16364471